TransCode Therapeutics announced positive Phase 1a results for its lead candidate TTX-MC138, showing safety, tolerability, and disease stabilization in metastatic cancer patients across all dose cohorts. The company will advance to Phase 2a development targeting ctDNA-positive colorectal cancer patients.